Technology
Health
Biotechnology

Conatus

$0.3103
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.0118 (-3.66%) As of 10:05 AM EDT today
-$0.0118 (-3.66%) Today

Why Robinhood?

You can buy or sell Conatus and other stocks, options, ETFs, and crypto commission-free!

About CNAT

Conatus Pharmaceuticals Inc. Common Stock, also called Conatus, is a biotechnology company, which engages in the development and commercialization of medicines for the treatment of liver diseases. Read More It focuses in development of emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease, which reduce the activities of human caspases. The company was founded by Alfred P. Spada, Jennifer Giottonini Cayer, and Steven J. Mento on July 13, 2005 and is headquartered in San Diego, CA.

Employees
31
Headquarters
San Diego, California
Founded
2005
Market Cap
10.68M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.67M
High Today
$0.3299
Low Today
$0.31
Open Price
$0.3284
Volume
65.85K
52 Week High
$6.74
52 Week Low
$0.25

Collections

Technology
Health
Biotechnology
2013 IPO
US
North America

CNAT Earnings

-$0.20
-$0.17
-$0.15
-$0.12
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Jul 31, After Hours

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.